Full-Time
Confirmed live in the last 24 hours
Develops genetic medicines for neurological diseases
Senior, Expert
Lexington, MA, USA
You match the following Voyager Therapeutics's candidate preferences
Employers are more likely to interview you if you match these preferences:
Voyager Therapeutics develops genetic medicines aimed at treating neurological diseases, particularly those affecting the central nervous system like amyotrophic lateral sclerosis (ALS). Their approach involves using a proprietary platform that utilizes adeno-associated virus (AAV) capsids to deliver genetic material directly to the brain through intravenous dosing, overcoming the challenge of the blood-brain barrier. Unlike many competitors, Voyager focuses on creating treatments that are specifically designed to address severe neurological conditions, and they emphasize collaboration with larger pharmaceutical companies to enhance their research and development efforts. The company's goal is to provide transformative therapies that significantly improve the lives of patients suffering from these debilitating diseases.
Company Size
201-500
Company Stage
IPO
Total Funding
$102.1M
Headquarters
Cambridge, Massachusetts
Founded
2014
Help us improve and share your feedback! Did you find this helpful?
Flexible Work Hours
At the start of 2024, Voyager Therapeutics announced that it would collaborate with Novartis to discover and develop next-generation gene therapies for SMA and other neurologic conditions.
Great Point Partners LLC invests $12.67 million in Voyager Therapeutics, Inc. (NASDAQ:VYGR).
Voyager Therapeutics appoints Nathan Jorgensen as Chief Financial Officer.
Improving Gene TherapyIn December 2023, the FDA made history by approving the first human gene therapy for sickle cell disease. This was quite a revolution and opened the way for much more gene therapy for other incurable diseases.One difficulty in all gene therapy procedures is getting enough of the intended genetic material delivered into the target cells. This can cause multiple issues, from too low gene modification to be efficient as a medicine to un-targeted cells being modified or immune reactions and side effects from too concentrated a dose. And, of course, using more than needed gene editing medicine is expensive.Luckily, researchers might have found a way to solve this issue, using electric pulses to boost the efficiency of gene transformation 40 times.Electricity For Gene EditingUsing electricity for gene modification is not really a new concept in itself, with electroporation a very ancient method used to create GMOs. However, in the case of this method, the damage inflicted on the cells by the very high voltage makes it only fit for modifying cell culture, bacteria, or plants, and not the gene inside a living animal or human.What the researchers at the University of Wisconsin–Madison have discovered is that gene therapies can be improved with a short pulse of electricity instead. This was done in collaboration between University of Wisconsin–Madison researchers ( Susan Hagness and John Booske and PhD student Yizhou Yao) and Hans Sollinger, a world-renowned transplant surgeon.Contrary to the more brutal electroporation method, the electric pulses are very quick, only 80 milliseconds long
LEXINGTON, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced it will report first quarter 2024 financial and operating results after market close on Monday, May 13, 2024. Subsequently, the Company will host a conference call and webcast at 4:30 p.m. ET to review its financial and operating results.To participate via telephone and join the call live, please register in advance here: https://register.vevent.com/register/BI1f6af80e7a614ca7925cbad2f35a55c6. Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique passcode. A live webcast of the call will also be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay of the call will be available at the same link approximately two hours after its completion
Cornercap Investment Counsel Inc. invests $196,000 in Voyager Therapeutics, Inc. (NASDAQ:VYGR).
LEXINGTON, Mass., April 16, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson’s disease and other GBA1-mediated diseases. The candidate combines a GBA1 gene replacement payload with an intravenously administered, blood-brain barrier penetrant, novel capsid derived from Voyager’s TRACER™ capsid discovery platform. The companies expect to file an Investigational New Drug (IND) application with the FDA for the program in 2025.Selection of the development candidate triggered a $3 million milestone payment to Voyager, which the Company expects to receive in the second quarter of 2024. Voyager is eligible to receive additional future development and commercialization milestone payments based on the further advancement of this program.“The nomination of this development candidate in the GBA1 program, following the recent nomination of a development candidate in the Friedreich’s ataxia program, demonstrates the productivity of the collaboration between Voyager and Neurocrine to advance gene therapies for neurological diseases,” said Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager
LEXINGTON, Mass. - Voyager Therapeutics, Inc. (NASDAQ:VYGR), a company focusing on neurogenetic medicine development, announced the appointment of Toby Ferguson, M.D., Ph.D., as its new Chief Medical Officer (CMO).
LEXINGTON, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the pricing of an underwritten public offering of 7,777,778 shares of its common stock at a public offering price of $9.00 per share, and, to investors who…
Voyager Therapeutics Inc. and Novartis AG signed a licensing agreement to develop treatments for neurological diseases.